Form 4: Enliven Therapeutics CFO Executes Pre-Arranged Stock Option Exercise and Share Sale

Enliven Therapeutics, Inc. Chief Financial Officer Benjamin Hohl exercised stock options and subsequently sold 3,000 shares of common stock on June 13, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (ELVN), engaged in stock transactions on June 13, 2025.
• He acquired 3,000 shares of common stock by exercising stock options at a price of $2.48 per share.
• Immediately following the exercise, he sold 3,000 shares of common stock at a weighted average price of $22.5518 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Hohl on June 26, 2023.
• After these transactions, Mr. Hohl directly beneficially owns 23,000 shares of common stock and 119,056 derivative securities (stock options).
• The stock option exercised was part of a larger grant of 262,120 shares, which vested 25% on August 2, 2022, with the remaining shares vesting in 36 equal monthly installments thereafter.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns about opportunistic trading. The significant profit from the option exercise is a positive for the individual, but the sale itself is a routine event for an executive managing their equity compensation.

Positives

• The exercise of stock options at a low price ($2.48) and subsequent sale at a significantly higher price ($22.5518) indicates a substantial personal gain for the CFO, reflecting the appreciation in the company's stock value since the options were granted.
• The transactions were conducted under a Rule 10b5-1 trading plan, which demonstrates pre-planning and reduces concerns about opportunistic insider trading.

Negatives

• The sale of 3,000 shares by a key executive (CFO) could be perceived by some investors as a negative signal regarding management's confidence in the company's near-term stock performance, despite being part of a pre-arranged plan.

Future Outlook

The document indicates that the remaining stock options granted to the CFO will continue to vest in 36 equal monthly installments following August 2, 2022, and have an expiration date of August 2, 2031.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide information relevant to broader industry trends or competitive analysis. It is a routine disclosure of executive stock activity.

Stakeholder Impact

• Shareholders: The sale of shares by a CFO, even under a 10b5-1 plan, might lead to minor negative sentiment or questions about management's long-term conviction, though the pre-arranged nature lessens this impact.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• Continued vesting of remaining stock options in 36 equal monthly installments.

Key Dates

Recommendation

Keywords

Enliven Therapeutics, ELVN, Benjamin Hohl, CFO, Form 4, SEC Filing, Insider Trading, Stock Options, Rule 10b5-1 Plan, Share Sale, Equity Transaction, Beneficial Ownership